CVS Health raised its 2026 earnings guidance and expanded its GLP-1 weight management collaboration with Eli Lilly, the company announced alongside second-quarter results. Revenue reached US$106.10 billion with net income of US$2,979 million, while sales came in at US$35,117 million. The expanded collaboration leverages CVS's integrated pharmacy, insurance, and care-delivery assets to capture growing demand for weight management treatments. The raised guidance reinforces near-term confidence in margin recovery, though elevated medical and pharmacy cost trends remain a key risk.
CVS Health CorpCVS raised 2026 guidance and reported Q2 results, reinforcing margin recovery confidence.
Eli Lilly and CompanyExpanded collaboration with CVS increases distribution and access for Lilly's GLP-1 treatments, boosting demand.
